Invesaro

Stocks Comparison

10x Genomics vs Waters: revenue, profit, margins and growth compared

10x Genomics brought in $642.8M of revenue in fiscal 2025, Waters $3.2B in fiscal 2025. Revenue changed by +5.2% at 10x Genomics and +7.0% at Waters on the year before, so Waters grew faster. 10x Genomics kept -6.8% of its revenue as net profit, Waters 20.3%. Free cash flow was $130.1M at 10x Genomics and $539.8M at Waters.

Side by side, latest fiscal year

TXGWAT
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$642.8M$3.2B
Revenue growth+5.2%+7.0%
Net income-$43.5M$642.6M
Net margin-6.8%20.3%
Free cash flow$130.1M$539.8M
Free cash flow margin20.2%17.1%
Earnings per share (diluted)-$0.35$10.76
Cash$474M$588M
Debtn/a$1.4B
Price to earningsn/a40.3
Market value$11.2B$42.6B
Dividend yieldn/an/a
Rank by revenue in sector#299 of 451 · Industrials#176 of 451 · Industrials

Over the years

Revenue
TXG FY2019: $146.3MTXG FY2019: $245.9MTXG FY2020: $298.8MTXG FY2021: $490.5MTXG FY2022: $516.4MTXG FY2023: $618.7MTXG FY2024: $610.8MTXG FY2025: $642.8MWAT FY2018: $2.4BWAT FY2019: $2.4BWAT FY2020: $2.4BWAT FY2021: $2.8BWAT FY2022: $3BWAT FY2023: $3BWAT FY2024: $3BWAT FY2025: $3.2BFY18FY19FY20FY21FY22FY23FY24FY25
TXG $642.8MWAT $3.2B
Net income
TXG FY2019: -$112.5MTXG FY2019: -$31.3MTXG FY2020: -$542.7MTXG FY2021: -$58.2MTXG FY2022: -$166MTXG FY2023: -$255.1MTXG FY2024: -$182.6MTXG FY2025: -$43.5MWAT FY2018: $593.8MWAT FY2019: $592.2MWAT FY2020: $521.6MWAT FY2021: $692.8MWAT FY2022: $707.8MWAT FY2023: $642.2MWAT FY2024: $637.8MWAT FY2025: $642.6MFY18FY19FY20FY21FY22FY23FY24FY25
TXG -$43.5MWAT $642.6M
Net margin
TXG FY2019: -76.9%TXG FY2019: -12.7%TXG FY2020: -181.6%TXG FY2021: -11.9%TXG FY2022: -32.1%TXG FY2023: -41.2%TXG FY2024: -29.9%TXG FY2025: -6.8%WAT FY2018: 24.5%WAT FY2019: 24.6%WAT FY2020: 22.1%WAT FY2021: 24.9%WAT FY2022: 23.8%WAT FY2023: 21.7%WAT FY2024: 21.6%WAT FY2025: 20.3%FY18FY19FY20FY21FY22FY23FY24FY25
TXG -6.8%WAT 20.3%
Revenue growth
TXG FY2019: +68.1%TXG FY2020: +21.5%TXG FY2021: +64.1%TXG FY2022: +5.3%TXG FY2023: +19.8%TXG FY2024: -1.3%TXG FY2025: +5.2%WAT FY2019: -0.6%WAT FY2020: -1.7%WAT FY2021: +17.8%WAT FY2022: +6.7%WAT FY2023: -0.5%WAT FY2024: +0.1%WAT FY2025: +7.0%FY19FY20FY21FY22FY23FY24FY25
TXG +5.2%WAT +7.0%
Free cash flow
TXG FY2019: -$82.7MTXG FY2019: -$8.1MTXG FY2020: -$254.6MTXG FY2021: -$122.7MTXG FY2022: -$165.3MTXG FY2023: -$63.8MTXG FY2024: -$5.7MTXG FY2025: $130.1MWAT FY2023: $442.2MWAT FY2024: $619.6MWAT FY2025: $539.8MFY19FY20FY21FY22FY23FY24FY25
TXG $130.1MWAT $539.8M

Fiscal years as each company reports them; the two may end in different months.

Questions about 10x Genomics and Waters

Which is bigger by revenue, 10x Genomics or Waters?

Waters is bigger by revenue: $3.2B in fiscal 2025, against $642.8M for 10x Genomics in fiscal 2025.

Which keeps more of its revenue as profit, 10x Genomics or Waters?

10x Genomics had a net margin of -6.8% in fiscal 2025; Waters had 20.3% in fiscal 2025.

Which grew revenue faster, 10x Genomics or Waters?

In their latest fiscal years revenue changed by +5.2% at 10x Genomics and +7.0% at Waters.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies